Articles from Oruka Therapeutics, Inc.

Continued operational excellence leading to acceleration of multiple timelines:

MENLO PARK, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, 2025, at 3:55 PM PT.

Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year

ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka’s addition will become effective prior to market open on Monday, December 23rd, 2024.

MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced participation and a fireside chat at Piper Sandler’s 36th Annual Healthcare Conference:

Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration

MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $200 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including a large investment manager, Braidwell LP, Venrock Healthcare Capital Partners, Fairmount, Access Biotechnology, Blackstone Multi-Asset Investing, Frazier Life Sciences, Paradigm BioCapital, RTW Investments LP, SR One, Janus Henderson Investors, Commodore Capital, Kalehua Capital, Avidity Partners, Affinity Healthcare Fund LP and Allostery Investments LP, among others.

ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025

Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions

Paul Quinlan joins as General Counsel

WALTHAM, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that Lawrence Klein, PhD, Chief Executive Officer will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 5:30 p.m. ET.

Joe Senn, PhD, joins as SVP of Nonclinical Research & Development

Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO

Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases